Drug
Biphasic Insulin Aspart 30
Biphasic Insulin Aspart 30: highest development phase Post-Market, developed by Novo Nordisk. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| biphasic insulin aspart 30 NCT00791895 | Post-Market | Diabetes |
| biphasic insulin aspart 30 NCT00825253 | Phase 1 | Diabetes |
Latest
No recent events.
Follow Biphasic Insulin Aspart 30 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.